OCC Targeted Therapy & Immunotherapy in Oncology 2

Question 1

Which immune checkpoint molecule does pembrolizumab (Keytruda) target?

Accepted Answer

PD-1

Answer

CTLA-4

Answer

PD-L1

Answer

LAG-3

Question 2

Ipilimumab was the first FDA-approved immune checkpoint inhibitor (2011) and targets which molecule?

Accepted Answer

CTLA-4 on T cells

Answer

PD-1 on T cells

Answer

PD-L1 on tumor cells

Answer

CD28 on T cells

Question 3

What is the first procedural step in manufacturing autologous CAR-T cell therapy for a patient?

Accepted Answer

Perform leukapheresis to collect the patient's T cells

Answer

Administer high-dose lymphodepleting chemotherapy

Answer

Administer G-CSF to mobilize stem cells

Answer

Perform a bone marrow biopsy to assess disease burden

Question 4

Which biomarker is most commonly used to predict response to PD-1/PD-L1 checkpoint inhibitors across multiple tumor types?

Accepted Answer

PD-L1 expression by immunohistochemistry (tumor proportion score)

Answer

HER2 gene amplification

Answer

BCR-ABL fusion transcript

Answer

KRAS mutation status

Question 5

Atezolizumab differs from pembrolizumab and nivolumab in that it targets which molecule?

Accepted Answer

PD-L1 on tumor and immune cells

Answer

PD-1 on T cells

Answer

CTLA-4 on T cells

Answer

LAG-3 on T cells

Question 6

Blinatumomab is a bispecific T-cell engager (BiTE) that simultaneously binds CD19 on B cells and which molecule on T cells?

Accepted Answer

CD3

Answer

PD-1

Answer

CD28

Answer

CTLA-4

Question 7

Microsatellite instability-high (MSI-H) status predicts response to PD-1 inhibitors. Which enzyme deficiency causes MSI-H tumors?

Accepted Answer

Mismatch repair (MMR) protein deficiency

Answer

Topoisomerase II deficiency

Answer

Thymidylate synthase deficiency

Answer

BRCA1/2 deficiency